WFG, WFO LASIK: How much HOA?

Article

Real-world data support wavefront-guided procedure with femtosecond laser flap creation

In young patients who present with low-to-moderate myopia, minimal astigmatism, and excellent optics, there is no doubt that wavefront-guided (WFG) LASIK with femtosecond laser flap creation is the refractive surgery procedure of choice, according to Dr Steven C. Schallhorn.

A database search was performed to find patients who matched a sample patient with the following baseline criteria: male gender, 28 years of age, myopia –3.5 to –4 D, cylinder <1 D, and a minimum follow-up of 1 month; 28 eyes of 20 patients were identified.

"These are phenomenal outcomes from a relevant, real-world population, and the data are consistent with my opinion that WFG LASIK is the best procedure to give the best possible outcome for patients represented by this specific clinical scenario," Dr Schallhorn said. "WFG LASIK gives the best visual quality with the least induction of higher-order aberration (HOA), and the latter is especially important in the situation where patients have very low pre-existing wavefront error. These individuals come in with excellent visual quality and demand it postoperatively."

In 2009, more than 90000 eyes were treated at an Optical Express centre. The 28 eyes identified after applying the search criteria had a mean manifest sphere of –3.77 D, mean manifest cylinder of –0.42 D, mean best-corrected visual acuity (BCVA) of 20/16, and mean low-light pupil diameter of 6.4 mm.

All had flap creation using the same femtosecond laser [IntraLase FS 60, Abbott Medical Optics (AMO)] and WFG treatment with the same excimer laser (VISX CustomVue, AMO) using a 6mm optical zone and 8mm transition zone.

At 1 month, mean ± SD manifest sphere was +0.05 ± 0.23 D, mean ± SD manifest cylinder was –0.12 ± 0.17 D, and mean UCVA was 20/16+1.

"Zero refraction was targeted for both manifest sphere and cylinder in these eyes, and for both endpoints, the achieved was extraordinarily close to the intended using the WFG procedure," Dr Schallhorn said.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.